Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
MYOS's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: No Debt )
MYOS' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: No Debt

Equity to Asset 0.87
MYOS's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 0.87 )
MYOS' s 10-Year Equity to Asset Range
Min: 0.17   Max: 0.96
Current: 0.87

0.17
0.96
Interest Coverage No Debt
MYOS's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: No Debt )
MYOS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 21.69
M-Score: 1.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -65.11
MYOS's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: -65.11 )
MYOS' s 10-Year Operating margin (%) Range
Min: -4642.42   Max: -128.6
Current: -65.11

-4642.42
-128.6
Net-margin (%) -65.05
MYOS's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: -65.05 )
MYOS' s 10-Year Net-margin (%) Range
Min: -5653.54   Max: -128.48
Current: -65.05

-5653.54
-128.48
ROE (%) -64.84
MYOS's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: -64.84 )
MYOS' s 10-Year ROE (%) Range
Min: -2665.24   Max: -89.39
Current: -64.84

-2665.24
-89.39
ROA (%) -57.75
MYOS's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: -57.75 )
MYOS' s 10-Year ROA (%) Range
Min: -2600   Max: -45
Current: -57.75

-2600
-45
ROC (Joel Greenblatt) (%) -272.10
MYOS's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: -272.10 )
MYOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -306400   Max: -739.51
Current: -272.1

-306400
-739.51
EBITDA Growth (%) 1587.20
MYOS's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 1587.20 )
MYOS' s 10-Year EBITDA Growth (%) Range
Min: -37   Max: 1587.2
Current: 1587.2

-37
1587.2
EPS Growth (%) 1588.70
MYOS's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 1588.70 )
MYOS' s 10-Year EPS Growth (%) Range
Min: -37   Max: 1588.7
Current: 1588.7

-37
1588.7
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.33
MYOS's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 6.33 )
MYOS' s 10-Year P/B Range
Min: 0.04   Max: 6.17
Current: 6.33

0.04
6.17
P/S 0.47
MYOS's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 0.47 )
MYOS' s 10-Year P/S Range
Min: 0.13   Max: 10
Current: 0.47

0.13
10
EV-to-EBIT -12.58
MYOS's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: -12.58 )
MYOS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -12.58

Current Ratio 5.47
MYOS's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 5.47 )
MYOS' s 10-Year Current Ratio Range
Min: 0.03   Max: 27.24
Current: 5.47

0.03
27.24
Quick Ratio 4.41
MYOS's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 4.41 )
MYOS' s 10-Year Quick Ratio Range
Min: 0.03   Max: 26.31
Current: 4.41

0.03
26.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 38.29
MYOS's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 38.29 )
MYOS' s 10-Year Price/Net Cash Range
Min: 0.12   Max: 34.02
Current: 38.29

0.12
34.02
Price/Net Current Asset Value 12.98
MYOS's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 12.98 )
MYOS' s 10-Year Price/Net Current Asset Value Range
Min: 0.11   Max: 11.53
Current: 12.98

0.11
11.53
Price/Tangible Book 8.72
MYOS's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 8.72 )
MYOS' s 10-Year Price/Tangible Book Range
Min: 0.1   Max: 7.75
Current: 8.72

0.1
7.75
Price/Median PS Value 1.09
MYOS's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: 1.09 )
MYOS' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 16
Current: 1.09

0.01
16
Forward Rate of Return (Yacktman) -3.31
MYOS's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. MYOS: -3.31 )
MYOS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -3.31

Business Description

Industry: »
Compare: » details
MYOS Corp is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.
» More Articles for NAS:MYOS

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage increases Sep 19 2014
MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct... Sep 18 2014
MYOS Corporation to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on... Sep 04 2014
MYOS CORP Financials Aug 22 2014
MYOS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 14 2014
MYOS CORP Files SEC form 10-Q, Quarterly Report Aug 14 2014
MYOS Corporation Reports 2014 Second Quarter Results Aug 14 2014
MYOS Corporation to Announce Second Quarter 2014 Financial Results on August 14, 2014 Aug 07 2014
MYOS Corporation Reports Additional Clinical Data on the Impact of Fortetropin on Lean Body Mass,... Aug 06 2014
MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer Jul 30 2014
MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin Jul 25 2014
MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jul 24 2014
MYOS receives patent allowance in U.S. Jul 24 2014
MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary... Jul 24 2014
MYOS Corp. Tackles Muscles Health Jul 22 2014
MYOS reports positive top-line clinical study results for Fortetropin Jul 22 2014
MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building... Jul 22 2014
MYOS announces agreement with Cloud Pharmaceuticals Jul 17 2014
MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules... Jul 17 2014
MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Jul 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK